Actinium Pharmaceuticals Provides Third Quarter 2026 Corporate Update Highlighting ATNM-400 and Other Business Progress
Announced HER3 as the target of ATNM-400 and presented initial data from the first-in- human HERACT-PRO-1 Phase 1/2a study in metastatic castration-resistant prostate cancer (mCRPC) at EANM 2026 Initiated RADIANZ pan-tumor imaging study to inform ATNM-400 development across multiple solid...